Tweets
I wouldn't sleep on this. 😴💤
Abstract 1413: In a PsA cohort, restless leg syndrome was linked to:
🔹 ↑ disease activity (polyarthritis, swollen joints, DAPSA)
🔹 Worse physical function (↑ HAQ)
🔹 Fatigue, anxiety, depression, & poorer sleep quality
@RheumNow #ACR25
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
2 months 3 weeks ago
Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod
Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43
Ongoing research, further data needed.
#ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW
sheila @RHEUMarampa ( View Tweet )
2 months 3 weeks ago
Really useful observational study, 305 pts with TAK
Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory
Majority of lesions stenotic. Emphasizes importance of regular monitoring
#ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym
Links:
Mike Putman @EBRheum ( View Tweet )
2 months 3 weeks ago
Infection data from SELECT-GCA:
Glucocorticoids seem to drive overall infectious risk
UPA use associated with higher zoster - vaccinate!!
@RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
2 months 3 weeks ago
Who with #SSc-ILD will progress?
progression is non linear - can stabilize and worsen
Search for Predictive biomarker
For clinical care & enriching RCTs
Maybe #KL6 🤷♀️
Maybe IP-10, MIG
No strong #biomarker
Depends on what is used
#ACR25 @RheumNow @ACRheum
Abst#0882 #0883 https://t.co/lyTRUEY9SI
Links:
Janet Pope @Janetbirdope ( View Tweet )
2 months 3 weeks ago
After At-risk RA, time to discuss At-risk PsA patients
ARP-PsA
Prospective cohort 1400+ pts
8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology)
Risk factors:
Pso >15 years
Pso + Family Hx
US synovitis/enthesitis
At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
2 months 3 weeks ago
Prednisone remains both lifeline and liability.
New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict.
@RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
Abstract 1431: Radiographic sacroiliitis in #PsA: insights from an Indian cohort
- Cervical and lumbosacral spine syndesmophytes were common
- Levels C5, C6, and L4 vertebrae frequently involved including syndesmophyte damage w/ non-marginal bridging
@RheumNow #ACR25
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
2 months 3 weeks ago
Picture this 👉radiographic joint damage tied to worse physical function in #PsA:
🔹 ↑ mSS → ↑ HAQ (β=0.003 [0.002–0.004])
🔹 ↑ mSS → ↓ SF-36 PF (β=−0.10 [−0.15 to −0.05])
🔹 ↑ # of damaged joints → worse physical function
@RheumNow #ACR25 Abstract 1425
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
2 months 3 weeks ago
Abstrat 1414 Compared to #PsO, early #PsA showed:
🔹 ↑ Dactylitis (66%), Enthesitis (78%), CRP/ESR
🔹 Longer morning stiffness & ↑TJC/SJC
🔹 MRI/US: frequent tenosynovitis & bone changes
🔹 Predictive model combining these features showed Sens 89%, Spec 84%
@RheumNow #ACR25
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
2 months 3 weeks ago
Abstract 0878: In PsA pts w/ lateral epicondyle enthesitis on secukinumab (n=11):
🔹 Improved DAPSA & SPARCC scores
🔹 entheseal tissue biopsy showing shift toward pro-resolving fibroblasts (↑DKK3/CD200⁺)
🔹 ↓ osteoblast-related pathways
@RheumNow #ACR25
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
2 months 3 weeks ago
Kuzkina et al. Efficacy of IL-6i with olokizumab on depression in RA. There appear to be some benefit but anti-depressants still needed. Group 1 is olokizumab alone, other 2 groups have anti-depressants also. @RheumNow #ACR25 Abstr#1323 https://t.co/h2ExYQgKTL
Richard Conway @RichardPAConway ( View Tweet )
2 months 3 weeks ago
